 | |
| Clinical data | |
|---|---|
| Other names | Deglymidodrine; ST-1059; 3,6-Dimethoxy-β-hydroxy-2-phenylethylamine |
| Drug class | α1-Adrenergic receptoragonist;Antihypotensive agent;Vasopressor |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.322.299 |
| Chemical and physical data | |
| Formula | C10H15NO3 |
| Molar mass | 197.234 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Desglymidodrine (developmental code nameST-1059) is theactive metabolite of theprodrugantihypotensive agentmidodrine.[1][2][3] It acts as aselectiveα1-adrenergic receptoragonist.[1][2][3] Desglymidodrine is formed from midodrine viadeglycination.[1][2][3]
Desglymidodrine, also known as 3,6-dimethoxy-β-hydroxy-2-phenylethylamine, is asubstituted phenethylaminederivative.[4][5]
Midodrine's experimentallog P is -0.5 and its predicted log P ranges from -0.49 to -0.95.[6][7] The predicted log P of desglymidodrine ranges from -0.01 to 0.15.[4][5]
Ananalogue of desglymidodrine isdimetofrine (3,5-dimethoxy-4,β-dihydroxy-N-methylphenethylamine).
{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)